<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1517-4522</journal-id>
<journal-title><![CDATA[Sociologias]]></journal-title>
<abbrev-journal-title><![CDATA[Sociologias]]></abbrev-journal-title>
<issn>1517-4522</issn>
<publisher>
<publisher-name><![CDATA[Programa de Pós-Graduação em Sociologia - UFRGS]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1517-45222019000100048</article-id>
<article-id pub-id-type="doi">10.1590/15174522-02105002</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Embodied values: post-pharmaceutical health and the accumulation of surplus vitality in regenerative stem cell medicine]]></article-title>
<article-title xml:lang="es"><![CDATA[Valores incorporados: salud post-farmacéutica y la acumulación de vitalidad excedente en la medicina de células madre regenerativas]]></article-title>
<article-title xml:lang="pt"><![CDATA[Valores incorporados: saúde pós-farmacêutica e o acúmulo de vitalidade excedente na medicina regenerativa com células-tronco]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Haddad]]></surname>
<given-names><![CDATA[Christian]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Austrian Institute for International Affairs  ]]></institution>
<addr-line><![CDATA[Vienna ]]></addr-line>
<country>Austria</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<volume>21</volume>
<numero>50</numero>
<fpage>48</fpage>
<lpage>79</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S1517-45222019000100048&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.br/scielo.php?script=sci_abstract&amp;pid=S1517-45222019000100048&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.br/scielo.php?script=sci_pdf&amp;pid=S1517-45222019000100048&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract This paper analyzes an emerging form of post-pharmaceutical health and its underlying regime of value in the global bioeconomy of regenerative stem cell-based medicine (RSCM). Animated by a vision to overcome drug-based therapies and their underlying political economies, RSCM pursues a form of regenerative health that is strikingly at odds with pharmaceutical regimes of drug research, regulation and therapy. To offer a theoretical account of these competing forms of health, the paper provides an analysis of the regimes of values that underpin pharmaceutical and regenerative health respectively. This analysis is done alongside three dimensions: the interlinkage between knowledge, technology and economic value creation; its relation to normative values and ethics; and conceptions and valuations of the biomedical subject and his/her body in biomedical research, intervention and innovation. Contrasting these two diverging regimes of health and value suggests that in RSCM the pharmaceutical logic of accumulating &#8220;surplus health&#8221; is not entirely dismissed but re-articulated in a regime based on the (re-)generation of regenerative biovalue through the extraction and ex vivo accumulation of &#8220;surplus vitality&#8221;. Finally, the article discusses &#8220;post-pharmaceutical health&#8221; as a sensitizing concept that offers new research avenues into emergent forms of health, value, and subjectivity beyond RSCM.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Este artículo analiza una forma emergente de salud post-farmacéutica y su régimen subyacente de valor en la bioeconomía global de la medicina regenerativa basada en células madre (MRCM). Animada por una visión de superación de las terapias basadas en medicamentos y sus economías políticas subyacentes, la MRCM persigue una forma de salud regenerativa que está marcadamente en desacuerdo con los regímenes farmacéuticos de investigación, regulación y terapia de medicamentos. Para ofrecer una explicación teórica de estas formas de salud en competencia, el artículo proporciona un análisis de los regímenes de valor que sustentan la salud farmacéutica y la regenerativa, respectivamente. Este análisis se hace según tres dimensiones: la interconexión entre el conocimiento, la tecnología y la creación de valor económico; su relación con los valores normativos y la ética; y las concepciones y valoraciones del sujeto biomédico y su cuerpo en la investigación, intervención e innovación biomédicas. El contraste de estos dos regímenes divergentes de salud y valor sugiere que en la MRCM la lógica farmacéutica de acumular &#8220;salud excedente&#8221; no se descarta completamente, sino que se rearticula en un régimen basado en la (re)generación de biovalor regenerativo a través de la extracción y la acumulación ex vivo de &#8220;vitalidad excedente&#8221;. Finalmente, el artículo analiza la &#8220;salud post-farmacéutica&#8221; como un concepto instigador que ofrece nuevas vías de investigación en formas emergentes de salud, valor y subjetividad más allá de la MRCM.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo Este artigo analisa uma forma emergente de saúde pós-farmacêutica e seu regime implícito de valor na bioeconomia global da medicina regenerativa baseada em células-tronco (MRCT). Estimulada por uma perspectiva de superação das terapias baseadas em medicação e suas economias políticas subjacentes, a medicina regenerativa com células-tronco (MRCT) busca uma forma de saúde regenerativa notavelmente dissonante dos regimes farmacológicos de pesquisa, regulação e terapia. Visando oferecer um enfoque teórico desses modelos de saúde concorrentes, este artigo oferece uma análise dos regimes de valores que sustentam a saúde farmacêutica e a saúde regenerativa, respectivamente. Essa análise se faz segundo três dimensões: as correlações entre conhecimento, tecnologia e criação de valor econômico; sua relação com valores normativos e a ética; e as concepções e valorações do sujeito biomédico e de seu corpo em pesquisa, intervenção e inovação biomédicas. A comparação entre esses dois regimes divergentes de saúde e valor sugere que na MRCT a lógica farmacêutica de acumular &#8220;saúde excedente&#8221; não é inteiramente descartada, mas rearticulada num regime baseado na re(produção) de biovalor regenerativo, por meio da extração e acumulação ex vivo de &#8220;vitalidade excedente&#8221;. Finalmente, o artigo discute a &#8220;saúde pós-farmacêutica&#8221; como um conceito provocativo que oferece novos caminhos de pesquisa para formas emergentes de saúde, valor e subjetividade para além da MRCT.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Bioeconomy]]></kwd>
<kwd lng="en"><![CDATA[Biovalue]]></kwd>
<kwd lng="en"><![CDATA[Health regimes]]></kwd>
<kwd lng="en"><![CDATA[Pharmaceuticals]]></kwd>
<kwd lng="en"><![CDATA[Regenerative stem cell medicine]]></kwd>
<kwd lng="en"><![CDATA[Regulatory pharmaceuticalization]]></kwd>
<kwd lng="es"><![CDATA[Bioeconomía]]></kwd>
<kwd lng="es"><![CDATA[Biovalor]]></kwd>
<kwd lng="es"><![CDATA[Regímenes de salud]]></kwd>
<kwd lng="es"><![CDATA[Medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Medicina regenerativa de células madre]]></kwd>
<kwd lng="es"><![CDATA[Farmacologización reguladora]]></kwd>
<kwd lng="pt"><![CDATA[Bioeconomia]]></kwd>
<kwd lng="pt"><![CDATA[Biovalor]]></kwd>
<kwd lng="pt"><![CDATA[Regimes de saúde]]></kwd>
<kwd lng="pt"><![CDATA[Medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[Medicina regenerativa de células-tronco]]></kwd>
<kwd lng="pt"><![CDATA[Farmacologização regulatória]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ABBOTT]]></surname>
<given-names><![CDATA[Alison]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stem-cell ruling riles researchers]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2013</year>
<volume>495</volume>
<numero>7442</numero>
<issue>7442</issue>
<page-range>418-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ABRAHAM]]></surname>
<given-names><![CDATA[John]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmaceuticalization of society in context: theoretical, empirical and health dimensions]]></article-title>
<source><![CDATA[Sociology]]></source>
<year>2010</year>
<volume>44</volume>
<page-range>603-22</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ANNAS]]></surname>
<given-names><![CDATA[George J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer and the constitution - Choice at life's end]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2007</year>
<volume>357</volume>
<page-range>408-13</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BERRY]]></surname>
<given-names><![CDATA[Carol]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The dividing line between the role of the FDA and the practice of medicine: a historical review and current analysis]]></article-title>
<source><![CDATA[Digital Access to Scholarship at Harvard]]></source>
<year>1997</year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BHARADWAJ]]></surname>
<given-names><![CDATA[Aditya]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experimental subjectification: the pursuit of human embryonic stem cells in India]]></article-title>
<source><![CDATA[Ethnos]]></source>
<year>2014</year>
<volume>79</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>84-107</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BHARADWAJ]]></surname>
<given-names><![CDATA[Aditya]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stem cell intersections: perspectives and experiences]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[BHARADWAJ]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Global perspectives on stem cell technologies]]></source>
<year>2018</year>
<page-range>1-24</page-range><publisher-loc><![CDATA[Cham ]]></publisher-loc>
<publisher-name><![CDATA[Palgrave MacMillan]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BLASIMME]]></surname>
<given-names><![CDATA[Alessandro]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Translating stem cells to the clinic: scientific societies and the making of regenerative medicine]]></article-title>
<source><![CDATA[Quaderni]]></source>
<year>2013</year>
<volume>2</volume>
<page-range>29-44</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BIEHL]]></surname>
<given-names><![CDATA[Joao]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmaceuticalization: AIDS treatment and global health politics]]></article-title>
<source><![CDATA[Anthropological Quarterly]]></source>
<year>2007</year>
<volume>80</volume>
<page-range>1083-126</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BROWN]]></surname>
<given-names><![CDATA[Nik]]></given-names>
</name>
<name>
<surname><![CDATA[KRAFT]]></surname>
<given-names><![CDATA[Alison]]></given-names>
</name>
<name>
<surname><![CDATA[MARTIN]]></surname>
<given-names><![CDATA[Paul]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The promissory pasts of blood stem cells]]></article-title>
<source><![CDATA[BioSocieties]]></source>
<year>2006</year>
<volume>1</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>329-48</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CLARKE]]></surname>
<given-names><![CDATA[Adele]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomedicalization: technoscientific transformations of health, illness, and U.S. biomedicine]]></article-title>
<source><![CDATA[American Sociological Review]]></source>
<year>2003</year>
<volume>68</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>161-94</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[COOPER]]></surname>
<given-names><![CDATA[Melinda]]></given-names>
</name>
</person-group>
<source><![CDATA[Life as surplus. Biotechnology and capitalism in the neoliberal era]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Seattle ]]></publisher-loc>
<publisher-name><![CDATA[University of Washington Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[COOPER]]></surname>
<given-names><![CDATA[Melinda]]></given-names>
</name>
<name>
<surname><![CDATA[WALDBY]]></surname>
<given-names><![CDATA[Catherine]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical labor: tissue donors and research subjects in the global bioeconomy]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[Duke University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CYRANOSKI]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[US drug regulator audits Texas stem-cell company]]></article-title>
<source><![CDATA[Nature News Blog]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DEAN]]></surname>
<given-names><![CDATA[Mitchell]]></given-names>
</name>
</person-group>
<source><![CDATA[Governmentality. Power and rule in modern society]]></source>
<year>2010</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Sage]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DUMIT]]></surname>
<given-names><![CDATA[Joseph]]></given-names>
</name>
</person-group>
<source><![CDATA[Drugs for life: how pharmaceutical companies define our health]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[Duke University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DUMIT]]></surname>
<given-names><![CDATA[Joseph]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prescription maximization and the accumulation of surplus health in the pharmaceutical industry: the Biomarx experiment]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[SUNDER RAJAN]]></surname>
<given-names><![CDATA[Kaushik]]></given-names>
</name>
</person-group>
<source><![CDATA[Lively capital: biotechnologies, ethics, and governance in global markets]]></source>
<year>2012</year>
<page-range>45-92</page-range><publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[Duke University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[EPSTEIN]]></surname>
<given-names><![CDATA[Steven]]></given-names>
</name>
</person-group>
<source><![CDATA[Impure science: AIDS, activism, and the politics of knowledge]]></source>
<year>1996</year>
<publisher-loc><![CDATA[Berkeley ]]></publisher-loc>
<publisher-name><![CDATA[University of California Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FAULKNER]]></surname>
<given-names><![CDATA[Alex]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tissue engineered technologies: regulatory pharmaceuticalization in the European Union]]></article-title>
<source><![CDATA[Innovation: The European Journal of Social Science Research]]></source>
<year>2012</year>
<volume>25</volume>
<page-range>389-408</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FOUCAULT]]></surname>
<given-names><![CDATA[Michel]]></given-names>
</name>
</person-group>
<source><![CDATA[Naissance de la clinique. Une archéologie du regard médical]]></source>
<year>1963</year>
<publisher-loc><![CDATA[Paris ]]></publisher-loc>
<publisher-name><![CDATA[Presses universitaires de France]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GIBBONS]]></surname>
<given-names><![CDATA[Sarah]]></given-names>
</name>
<name>
<surname><![CDATA[NOVAS]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
</person-group>
<source><![CDATA[Biosocialities, genetics and the social sciences. Making biologies and identities]]></source>
<year>2008</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Routledge]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GOTTWEIS]]></surname>
<given-names><![CDATA[Herbert]]></given-names>
</name>
<name>
<surname><![CDATA[SALTER]]></surname>
<given-names><![CDATA[Brian]]></given-names>
</name>
<name>
<surname><![CDATA[WALDBY]]></surname>
<given-names><![CDATA[Catherine]]></given-names>
</name>
</person-group>
<source><![CDATA[The global politics of human embryonic stem cell science]]></source>
<year>2009</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Palgrave Macmillan]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HADDAD]]></surname>
<given-names><![CDATA[Christian]]></given-names>
</name>
</person-group>
<source><![CDATA[Zwischen Labor und Gesellschaft. Zur Biopolitik klinischer Forschung am Menschen]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Frankfurt ]]></publisher-loc>
<publisher-name><![CDATA[Peter Lang]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HADDAD]]></surname>
<given-names><![CDATA[Christian]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Services in the self: embodied labor and the global bioeconomy]]></article-title>
<source><![CDATA[Life Sciences, Society and Policy]]></source>
<year>2015</year>
<volume>11</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HADDAD]]></surname>
<given-names><![CDATA[Christian]]></given-names>
</name>
</person-group>
<source><![CDATA[The biopolitics of innovation: (re-)articulating visions and values of research, regulation and experimentation in the making of regenerative stem cell medicine]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Austria ]]></publisher-loc>
<publisher-name><![CDATA[Faculty for Social Sciences, University of Vienna]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HADDAD]]></surname>
<given-names><![CDATA[Christian]]></given-names>
</name>
<name>
<surname><![CDATA[CHEN]]></surname>
<given-names><![CDATA[Haidan]]></given-names>
</name>
<name>
<surname><![CDATA[GOTTWEIS]]></surname>
<given-names><![CDATA[Herbert]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unruly objects: novel innovation paths and their regulatory challenge]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[WEBSTER]]></surname>
<given-names><![CDATA[Andrew]]></given-names>
</name>
</person-group>
<source><![CDATA[The global dynamics of regenerative medicine]]></source>
<year>2013</year>
<page-range>88-117</page-range><publisher-loc><![CDATA[Houndsmill ]]></publisher-loc>
<publisher-name><![CDATA[Palgrave MacMillan]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HAUSKELLER]]></surname>
<given-names><![CDATA[Christine]]></given-names>
</name>
<name>
<surname><![CDATA[BELTRAME]]></surname>
<given-names><![CDATA[Lorenzo]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The hybrid bioeconomy of umbilical cord blood banking: re-examining the narrative of opposition between public and private services]]></article-title>
<source><![CDATA[BioSocieties]]></source>
<year>2016</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>415-34</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="book">
<collab>ISSCR</collab>
<source><![CDATA[Guidelines for the clinical translation of stem cells]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Skokie ]]></publisher-loc>
<publisher-name><![CDATA[ISSCR]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KLEINMANN]]></surname>
<given-names><![CDATA[Arthur]]></given-names>
</name>
<name>
<surname><![CDATA[PETRYNA]]></surname>
<given-names><![CDATA[Adriana]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pharmaceutical nexus]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[PETRYNA]]></surname>
<given-names><![CDATA[Adriana]]></given-names>
</name>
<name>
<surname><![CDATA[LAKOFF]]></surname>
<given-names><![CDATA[Andrew]]></given-names>
</name>
<name>
<surname><![CDATA[KLEINMANN]]></surname>
<given-names><![CDATA[Arthur]]></given-names>
</name>
</person-group>
<source><![CDATA[Global pharmaceuticals. Ethics, markets, practices]]></source>
<year>2006</year>
<page-range>1-32</page-range><publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[Duke University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LARSEN]]></surname>
<given-names><![CDATA[Lars]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Speaking truth to biopower: on the genealogy of bioeconom]]></article-title>
<source><![CDATA[Distinktion: Scandinavian Journal of Social Theory]]></source>
<year>2007</year>
<volume>8</volume>
<page-range>9-24</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LEMKE]]></surname>
<given-names><![CDATA[Thomas]]></given-names>
</name>
</person-group>
<source><![CDATA[Biopolitics. An advanced introduction]]></source>
<year>2011</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[New York University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LETTOW]]></surname>
<given-names><![CDATA[Susanne]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biokapitalismus und Inwertsetzung der Körper]]></article-title>
<source><![CDATA[PROKLA - Zeitschrift für kritische Sozialwissenschaft]]></source>
<year>2015</year>
<volume>178</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-49</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MARKS]]></surname>
<given-names><![CDATA[Harry]]></given-names>
</name>
</person-group>
<source><![CDATA[The progress of experiment. Science and therapeutic reform in the United States, 1900-1990]]></source>
<year>1997</year>
<publisher-loc><![CDATA[Cambridge ]]></publisher-loc>
<publisher-name><![CDATA[Cambridge University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGOEY]]></surname>
<given-names><![CDATA[Linsey]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Strategic unknowns: towards a sociology of ignorance]]></article-title>
<source><![CDATA[Economy &amp; Society]]></source>
<year>2012</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MORRISON]]></surname>
<given-names><![CDATA[Michael]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Promissory futures and possible pasts: the dynamics of contemporary expectations in regenerative medicine]]></article-title>
<source><![CDATA[BioSocieties]]></source>
<year>2012</year>
<volume>7</volume>
<page-range>3-22</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PETRYNA]]></surname>
<given-names><![CDATA[Adriana]]></given-names>
</name>
</person-group>
<source><![CDATA[When experiments travel. Clinical trials and the global search for human subjects]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Princeton ]]></publisher-loc>
<publisher-name><![CDATA[Princeton University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<collab>PR NEWSWIRE</collab>
<article-title xml:lang=""><![CDATA[Colorado medical clinic welcomes opportunity to fight FDA in court]]></article-title>
<source><![CDATA[PR Newswire]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ROSE]]></surname>
<given-names><![CDATA[Nikolas]]></given-names>
</name>
<name>
<surname><![CDATA[NOVAS]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biological citizenship]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[ONG]]></surname>
<given-names><![CDATA[Andrew]]></given-names>
</name>
<name>
<surname><![CDATA[COLLIER]]></surname>
<given-names><![CDATA[Stephen]]></given-names>
</name>
</person-group>
<source><![CDATA[Global assemblages: technology, politics, and ethics as anthropological problems]]></source>
<year>2005</year>
<page-range>439-63</page-range><publisher-loc><![CDATA[Malden ]]></publisher-loc>
<publisher-name><![CDATA[Blackwell Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ROSEMANN]]></surname>
<given-names><![CDATA[Achim]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global regulatory developments for clinical stem cell research: diversification and challenges to collaborations]]></article-title>
<source><![CDATA[Regenerative medicine]]></source>
<year>2016</year>
<volume>11</volume>
<page-range>647-57</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ROSEMANN]]></surname>
<given-names><![CDATA[Achim]]></given-names>
</name>
<name>
<surname><![CDATA[CHAISINTHROP]]></surname>
<given-names><![CDATA[Nattaka]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pluralization of the international: resistance and alter-standardization in regenerative stem cell medicine]]></article-title>
<source><![CDATA[Social Studies of Science]]></source>
<year>2016</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>112-39</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SALTER]]></surname>
<given-names><![CDATA[Brian]]></given-names>
</name>
<name>
<surname><![CDATA[ZHOU]]></surname>
<given-names><![CDATA[Yinhua]]></given-names>
</name>
<name>
<surname><![CDATA[DATTA]]></surname>
<given-names><![CDATA[Saheli]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hegemony in the marketplace of biomedical innovation: consumer demand and stem cell science]]></article-title>
<source><![CDATA[Social Science &amp; Medicine]]></source>
<year>2015</year>
<volume>131</volume>
<page-range>156-63</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SIPP]]></surname>
<given-names><![CDATA[Douglas]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marketing of unproven stem cell-based interventions: a call to action]]></article-title>
<source><![CDATA[Science translational medicine]]></source>
<year>2017</year>
<volume>9</volume>
<numero>397</numero>
<issue>397</issue>
</nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SUNDER RAJAN]]></surname>
<given-names><![CDATA[Kaushik]]></given-names>
</name>
</person-group>
<source><![CDATA[Biocapital: the constitution of postgenomic life]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[Duke University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SUNDER RAJAN]]></surname>
<given-names><![CDATA[Kaushik]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmocracy: value, politics, and knowledge in global biomedicine]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Durham ]]></publisher-loc>
<publisher-name><![CDATA[Duke University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SUNDER RAJAN]]></surname>
<given-names><![CDATA[Kaushik]]></given-names>
</name>
<name>
<surname><![CDATA[LEONELLI]]></surname>
<given-names><![CDATA[Sabina]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Introduction: biomedical trans-actions, postgenomics, and knowledge/value]]></article-title>
<source><![CDATA[Public Culture]]></source>
<year>2013</year>
<volume>25</volume>
<page-range>463-75</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<collab>TERSAL</collab>
<article-title xml:lang=""><![CDATA[Stop FDA shutting down adult stem cell research]]></article-title>
<source><![CDATA[Care2]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[THOMPSON]]></surname>
<given-names><![CDATA[Charis]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Foreword. Good science, better patients]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[BHARADWAJ]]></surname>
<given-names><![CDATA[Aditya]]></given-names>
</name>
</person-group>
<source><![CDATA[Global perspectives on stem cell technologies]]></source>
<year>2018</year>
<page-range>v-x</page-range><publisher-loc><![CDATA[Chams ]]></publisher-loc>
<publisher-name><![CDATA[Palgrave MacMillan]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WAHLBERG]]></surname>
<given-names><![CDATA[Ayo]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Knowledge of living]]></article-title>
<source><![CDATA[Somatosphere]]></source>
<year>2014</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WAHLBERG]]></surname>
<given-names><![CDATA[Ayo]]></given-names>
</name>
<name>
<surname><![CDATA[McGOEY]]></surname>
<given-names><![CDATA[Linsey]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An elusive evidence base: the construction and governance of randomized controlled trials]]></article-title>
<source><![CDATA[BioSocieties]]></source>
<year>2007</year>
<volume>2</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WALDBY]]></surname>
<given-names><![CDATA[Catherine]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stem cells, tissue cultures and the production of biovalue]]></article-title>
<source><![CDATA[Health]]></source>
<year>2002</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>305-23</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WEBSTER]]></surname>
<given-names><![CDATA[Andrew]]></given-names>
</name>
</person-group>
<source><![CDATA[The global dynamics of regenerative medicine: a social science critique]]></source>
<year>2013</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Palgrave Macmillan]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WILSON]]></surname>
<given-names><![CDATA[James]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A history lesson for stem cells]]></article-title>
<source><![CDATA[Science]]></source>
<year>2009</year>
<volume>324</volume>
<page-range>727-8</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WOOLHOUSE]]></surname>
<given-names><![CDATA[Mark]]></given-names>
</name>
<name>
<surname><![CDATA[FARRAR]]></surname>
<given-names><![CDATA[Jeremy]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Policy: an intergovernmental panel on antimicrobial resistance]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2014</year>
<volume>509</volume>
<numero>7502</numero>
<issue>7502</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
